OTL Intellectual Properties Newsletters

The Office of Technology Licensing (OTL) publishes a newsletter to provide information related to St. Jude intellectual property, including licensing income received, inventor allocations, patent activities and U.S. patents granted to St. Jude. Different technologies and agreements with industry are highlighted in each edition.

Technology Licensing Newsletter 2017

Intellectual Property Newsletter 2017

In this issue:

  • Patients Around the World Benefit From St. Jude Research Through OTL Licensing Efforts
  • Flu Vaccine Made For 14 Million Humans In U.S., Billions More Doses Worldwide
  • Alk Inhibitor Treatments For Childhood Leukemia And Adult Lung Cancer
  • Chimeric Antigen Receptor Immunotherapies Get Closer To Approval
  • Gene Therapy For Hemophilia B
  • Taci Treatment For Neuropathy
  • Gene Therapy Vector To Treat XSCID In Infants
  • Tpmt Diagnostic Helps Get Treatment Right For 200,000
  • 100,000 B-Cell Tests A Year For CD-19
  • Inventors Receive More Than $5 Million From FY2016 License Revenue
  • St. Jude OTL Celebrates Technology Transfer Professionals Day
  • St. Jude OTL Conducts Surveys For Clinical And Laboratory Staff, Faculty, And Post-Docs
  • Regional Tech Transfer Professionals Hosted by OTL
 
Technology Licensing Newsletter 2015

Intellectual Property Newsletter 2015

In this issue:

  • A Chimeric Antigen Receptor Developed at St. Jude Shows Promise in Immunotherapy
  • St. Jude OTL Recognized by U. S.  Chamber of Commerce
  • OTL Celebrates the Inaugural Technology Transfer Professionals Day and Two Important Anniversaries
  • A Brief History of the OTL at St. Jude
  • What is the Bayh-Dole Act?
  • Regional Tech Transfer Processionals Visit St. Jude
  • It Pays to Work with the OTL
 
Technology Licensing Newsletter 2014

Intellectual Property Newsletter 2014

In this issue:

  • Office of Technology Licensing: "How We Fit In"
  • LIFESCITN Academic Alliance Reunites Researches in Networking
  • New Antibiotics Effective Against Drug-Resistant Infections
  • OTL Revenue and Patents Report